Aprepitant for Postoperative Nausea and Vomiting
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this research is to study whether adding an FDA approved medication called aprepitant (a medication given to patients like you to reduce or eliminate nausea and vomiting) to the usual treatment to prevent nausea and vomiting given to patients during knee replacement surgery helps more patients go home on the same day of surgery (before midnight) by eliminating nausea and vomiting.
Who Is on the Research Team?
Steven Greenberg, MD
Principal Investigator
Endeavor Health
Are You a Good Fit for This Trial?
This trial is for adults aged 18-90 having a planned, single knee replacement surgery with regional anesthesia. Participants must be able to take ondansetron and dexamethasone, speak English or Spanish, and be able to give consent and complete surveys.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Preoperative
Participants receive either aprepitant or placebo preoperatively, along with standard antiemetic protocol
Postoperative Monitoring
Participants are monitored for nausea and vomiting, and receive rescue antiemetics as needed
Follow-up
Participants are monitored for safety and effectiveness after treatment, including readmission rates and adverse events
What Are the Treatments Tested in This Trial?
Interventions
- Aprepitant
Trial Overview
The study tests if adding aprepitant (an anti-nausea drug) to the usual medications (ondansetron and dexamethasone) helps prevent nausea after knee replacement surgery so more patients can go home the same day. Some participants may receive a placebo instead of aprepitant.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Single intravenous (IV) bolus of 32mg aprepitant preoperatively , in addition to the standard antiemetic protocol (4 mg IV dexamethasone after induction of MAC sedation anesthesia and 4 mg IV ondansetron at surgical closure)
Single intravenous (IV) bolus of 32mg of placebo preoperatively, in addition to the standard antiemetic protocol (4 mg IV dexamethasone after induction of MAC sedation anesthesia and 4 mg IV ondansetron at surgical closure)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Endeavor Health
Lead Sponsor
Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.)
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.